Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001213900-25-012192·RIGEL PHARMACEUTICALS INC
Schedule 13G ownership disclosure
Rigel Pharmaceuticals Inc
Common Stock, $0.001 par value per share · CUSIP: 766559702
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Soleus Capital Master Fund, L.P.
Shares: 1,130,679.00 · Class: 6.4%
- Soleus Capital, LLC
Shares: 1,130,679.00 · Class: 6.4%
- Soleus Capital Group, LLC
Shares: 1,130,679.00 · Class: 6.4%
- Soleus Capital Management, L.P.
Shares: 1,130,679.00 · Class: 6.4%
- Soleus GP LLC
Shares: 1,130,679.00 · Class: 6.4%
- Guy Levy
Shares: 1,130,679.00 · Class: 6.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-012192
- Form type
- SCHEDULE 13G/A
- Filer
- RIGEL PHARMACEUTICALS INC
- CIK
- CIK 1034842
- Filed
- Feb 11, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership